| Ticker: DCRN | Charlestown Navy Yard, Building 96, 13th Street | |
| Exchange: NASDAQ-National Market | Charleston, Massachusetts 02129 | |
| Industry: Manufacturing | (617) 242-9100 |
| Type of Shares: | Common Shares | Filing Date: | 12/22/95 | |
| U.S. Shares: | 2,500,000 | Offer Date: | 2/12/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $14.00 - $16.00 | |
| Primary Shares: | 2,500,000 | Offer Price: | $8.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.56 | |
| Offering Amount: | $37,500,000 | Selling: | $0.32 | |
| Expenses: | $450,000 | Reallowance: | $0.10 | |
| Shares Out After: | 12,374,979 |
| Manager | Tier | Phone |
| PaineWebber Incorporated | Lead Manager | (212) 713-2626 |
| Vector Securities International, Inc. | Co-manager | (708) 940-1970 |
| Auditor: Arthur Andersen | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/94 | 9/30/95 | 9/30/94 | 9/30/95 | ||
| Revenue: | $0.00 | $0.00 | $0.00 | Assets: | $6.38 |
| Net Income: | -$5.85 | -$4.19 | -$4.67 | Liabilities: | $8.73 |
| EPS: | -$0.58 | -$0.42 | -$0.47 | Equity: | -$2.34 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is a developmental stage company that is currently investigating the use of animal cells to treat human diseases. Diacrin is developing proprietary populations of transplantable porcine cells for the treatment of human diseases which are characterized by cell dysfunction or cell death and for which current therapies are either inadequate or nonexistent. While the feasibility of cell transplantation has been demonstrated clinically by others, widespread use in clinical applications has been hampered by the lack of an adequate supply of human donor cells. To overcome this constraint, Diacrin has pioneered the use of porcine cells for clinical transplantation. The Company believes that pigs will be a reliable source of a wide range of cell types suitable for transplantation into humans. |
| Use of Proceeds |
| The company intends to use the net proceeds, including interest thereon, to fund research, development and clinical testing and for working capital and general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.